- Radiopharm Theranostics reported a **quarter-end cash balance of A$19.04 million** as of September 30, 2025, with **net cash outflows from operating activities totaling A$9.29 million** for the quarter.  **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:2]** **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:3]** **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:4]** 
- Subsequent to the quarter, the company completed an **A$35 million institutional placement** and launched an **A$5 million Share Purchase Plan**, which, combined with existing cash, is expected to extend its funding runway into **2027**.  **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:0]** **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:2]** 
- The company received **IND approval from the FDA** to initiate a Phase I therapeutic clinical study for Betabart (RV-01), a radiopharmaceutical therapy targeting B7H3, with the study planned to commence in the fourth quarter of 2025.  **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:0]** **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:1]** 
- Positive clinical updates were provided across four programs, including encouraging results from the **RAD 101 Phase 2b imaging study** and higher-than-expected tumor uptake in the **RAD 202 Phase 1 'HEAT' trial**.  **[1949257_0001213900-25-102795_ea026274801ex99-1_radio.htm:0]**

Radiopharm Theranostics Reports Q1 2026 Financials and Clinical Progress

- Radiopharm Theranostics Ltd (RADX) completed an **A$35 million** institutional private placement and launched an **A$5 million** Share Purchase Plan (SPP), raising approximately **A$40 million**.  **[1949257_0001213900-25-100126_ea026177901ex99-1_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:11]**  **Lantheus Holdings, Inc.** invested **A$7.6 million** (US$5.0 million) in the placement, increasing its shareholding to **14.5%**.  **[1949257_0001213900-25-100126_ea026177901ex99-1_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-1_radiopharm.htm:1]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:11]** 
- With an existing cash balance of **A$19 million** as of September 30, 2025, the company now has **A$59 million** in total funds, extending its funding runway into **2027**.  **[1949257_0001213900-25-100126_ea026177901ex99-1_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:11]**  These funds are primarily allocated to **clinical trials (A$34 million)** and **drug manufacturing (A$6 million)**.  **[1949257_0001213900-25-100126_ea026177901ex99-1_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:11]** 
- RADX reported positive clinical updates across four programs (RAD 101, RAD 202, RAD 204, RAD 301), with interim data showing promising results.  **[1949257_0001213900-25-100126_ea026177901ex99-2_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:10]**  Key milestones include topline results for RAD 101 by **H1 2026** and data for RAD 202 by **year-end 2025**.  **[1949257_0001213900-25-100126_ea026177901ex99-2_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:10]**  The company also plans to initiate Phase 1 trials for RV01 and RAD402 by **year-end 2025**.  **[1949257_0001213900-25-100126_ea026177901ex99-2_radiopharm.htm:0]** **[1949257_0001213900-25-100126_ea026177901ex99-3_radiopharm.htm:9]**

Radiopharm Theranostics Completes A$35M Placement and Provides Positive Clinical Updates

- **Radiopharm Theranostics** has entered into a research and option agreement with **Starpharma** to develop a novel radiotherapy asset.  **[1949257_0001213900-25-093349_ea025941901ex99-1_radio.htm:0]** 
- This collaboration aims to combine Radiopharm's radiopharmaceutical molecule with Starpharma's proprietary **DEP® platform technology** to create a new drug conjugate.  **[1949257_0001213900-25-093349_ea025941901ex99-1_radio.htm:0]** 
- Should Radiopharm exercise its exclusive option to license the developed asset, it would involve an **AUD $0.5 million option fee**, an **AUD $2 million upfront payment**, and potential **milestone payments of up to AUD $89 million**, in addition to royalties on net sales, payable to Starpharma.  **[1949257_0001213900-25-093349_ea025941901ex99-1_radio.htm:0]**

Radiopharm Theranostics Partners with Starpharma for Radiotherapy Development

- Radiopharm Theranostics Limited reported a **20.2% decrease** in loss from ordinary activities after tax, totaling **($36,703,089)** for the year ended **June 30, 2025**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- Revenue from contracts with customers significantly increased by **1114.3%** to **$3,633,422** for the year ended **June 30, 2025**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- Net assets grew to **$42,871,904** and cash reserves to **$29,116,835** as of **June 30, 2025**, primarily due to capital raises.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:3]** 
- The company increased its ownership in Radiopharm Ventures from 51% to **75%** on **August 26, 2024**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- The financial statements for the year ended **June 30, 2025**, are currently undergoing audit, with the final audited report anticipated by mid-September 2025.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]**

Radiopharm Theranostics (RADX)